{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:29Z","timestamp":1793090309759,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105545","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:16:27Z","timestamp":1787411787000},"page":"105545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From site-centered to patient-centered: Promises and challenges of decentralized clinical trials in oncology"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2714-2769","authenticated-orcid":false,"given":"Gabriella","family":"Gentile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Gerosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia","family":"Lobo-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105545_bib1","unstructured":"\u2018Conducting Clinical Trials With Decentralized Elements | FDA\u2019. n.d. Accessed 25 November 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements."},{"key":"10.1016\/j.critrevonc.2026.105545_bib2","unstructured":"\u2018Facilitating Decentralised Clinical Trials in the EU | European Medicines Agency (EMA)\u2019. 2022. December 19. https:\/\/www.ema.europa.eu\/en\/news\/facilitating-decentralised-clinical-trials-eu."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105545_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20053","article-title":"Association of remote technology use and other decentralization tools with patient likelihood to enroll in cancer clinical trials","volume":"5","author":"Adams","year":"2022","journal-title":"JAMA Netw. Open."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105545_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-022-00687-1","article-title":"Systemic therapy for early-stage breast cancer: learning from the past to build the future","volume":"19","author":"Agostinetto","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105545_bib5","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41591-024-03323-w","article-title":"Recommendations to promote equity, diversity and inclusion in decentralized clinical trials","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat. Med."},{"issue":"January","key":"10.1016\/j.critrevonc.2026.105545_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12874-021-01478-5","article-title":"Oncologic patients\u2019 misconceptions may impede enrollment into clinical trials: a cross-sectional study","volume":"22","author":"Asher","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105545_bib7","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.14694\/EdBook_AM.2015.35.e132","article-title":"The global conduct of cancer clinical trials: challenges and opportunities","author":"Barrios","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105545_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70117","article-title":"Decentralized clinical trials in the era of real-world evidence: a statistical perspective","volume":"18","author":"Chen","year":"2025","journal-title":"Clin. Transl. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105545_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/atm-23-5","article-title":"Despite negative perceptions of clinical trial conduct during the coronavirus disease 2019 (COVID-19) pandemic, are decentralized clinical trial methods here to stay?","volume":"11","author":"Cooper","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105545_bib10","doi-asserted-by":"crossref","DOI":"10.2196\/39910","article-title":"Enrollment and retention of participants in remote digital health studies: scoping review and framework proposal","volume":"24","author":"Daniore","year":"2022","journal-title":"J. Med. Internet Res."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105545_bib11","article-title":"Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center","volume":"41","author":"Davidson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"May","key":"10.1016\/j.critrevonc.2026.105545_bib12","article-title":"Digitizing the informed consent process: a review of the regulatory landscape in the European union","volume":"9","author":"De Sutter","year":"2022","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105545_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s43441-022-00454-5","article-title":"Assessing the financial value of decentralized clinical trials","volume":"57","author":"DiMasi","year":"2023","journal-title":"Ther. Innov. & Regul. Sci."},{"key":"10.1016\/j.critrevonc.2026.105545_bib14","doi-asserted-by":"crossref","unstructured":"DiMasi, Joseph A., and Michael Wilkinson. 2020. \u2018The financial benefits of faster development times: integrated formulation development, real-time manufacturing, and clinical testing\u2019, ahead of print, November. https:\/\/doi.org\/10.1007\/s43441-020-00172-w.","DOI":"10.1007\/s43441-020-00172-w"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105545_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8739","article-title":"Barriers to clinical trial implementation among community care centers","volume":"7","author":"Ebrahimi","year":"2024","journal-title":"JAMA Netw. Open."},{"issue":"10512","key":"10.1016\/j.critrevonc.2026.105545_bib16","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023","volume":"406","author":"Force","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105545_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41746-022-00603-y","article-title":"Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion","volume":"5","author":"Goodson","year":"2022","journal-title":"Npj Digit. Med."},{"issue":"July","key":"10.1016\/j.critrevonc.2026.105545_bib18","article-title":"Patients\u2019 daily reporting of symptoms via mobile application reveals a significant difference between patients\u2019 perceptions and doctors\u2019 interpretations","volume":"15","author":"Gra\u0161i\u010d Kuhar","year":"2025","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105545_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.17204","article-title":"A multiregional decentralized clinical trial program to improve access","volume":"9","author":"Haddad","year":"2026","journal-title":"JAMA Netw. Open."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105545_bib20","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.2024.6281","article-title":"Survival benefit associated with participation in clinical trials of anticancer drugs","volume":"331","author":"Iskander","year":"2024","journal-title":"JAMA"},{"issue":"6711","key":"10.1016\/j.critrevonc.2026.105545_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.adq4994","article-title":"The value of decentralized clinical trials: inclusion, accessibility, and innovation","volume":"385","author":"Jean-Louis","year":"2024","journal-title":"Science"},{"issue":"July","key":"10.1016\/j.critrevonc.2026.105545_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41746-025-01811-y","article-title":"Understanding the gap between expectations and reality in decentralized clinical trials","volume":"8","author":"Jiang","year":"2025","journal-title":"NPJ Digit. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105545_bib23","article-title":"Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: the case of decentralized clinical trial approaches","volume":"29","author":"Jong","year":"2024","journal-title":"Drug. Discov. Today"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105545_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57020","article-title":"Understanding of clinical trials among patients with cancer and their relatives","volume":"8","author":"Kubilay Tolunay","year":"2025","journal-title":"JAMA Netw. Open."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105545_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11684-024-1058-6","article-title":"Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics","volume":"18","author":"Li","year":"2024","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105545_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/oncolo\/oyad237","article-title":"Researcher experience and comfort with telemedicine and remote patient monitoring in cancer treatment trials","volume":"29","author":"Lichtenstein","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105545_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.70075","article-title":"Selecting and preparing clinical sites for the successful conduct of decentralized clinical trial activities-findings from the trials@home RADIAL proof-of-concept trial","author":"Lipinska","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105545_bib28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/bcp.15040","article-title":"When innovation outpaces regulations: the legal challenges for direct-to-patient supply of investigational medicinal products","volume":"88","author":"Malone","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3, ement","key":"10.1016\/j.critrevonc.2026.105545_bib29","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.gim.2022.01.223","article-title":"eP187: decentralization of clinical trials in the era of COVID-19: implications for rare disease trials","volume":"24","author":"Manjrekar","year":"2022","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105545_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13063-022-06959-6","article-title":"Electronic informed consent: effects on enrolment, practical and economic benefits, challenges, and drawbacks-a systematic review of studies within randomized controlled trials","volume":"24","author":"Mazzochi","year":"2023","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105545_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","article-title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","volume":"7","author":"Mills","year":"2006","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105545_bib32","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1111\/cts.13659","article-title":"Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European clinical trials register data","volume":"16","author":"Moraga Alapont","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105545_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.36401\/JIPO-23-33","article-title":"Decentralized clinical trials in early drug development\u2014a framework proposal","volume":"7","author":"Silva","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105545_bib34","article-title":"Implementing decentralized clinical trials in australia through teletrials: where to from here?","author":"Symons","year":"2024","journal-title":"Ther. Innov. & Regul. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105545_bib35","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/S1470-2045(16)30572-1","article-title":"Relevance of randomised controlled trials in oncology","volume":"17","author":"Tannock","year":"2016","journal-title":"Lancet Oncol."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105545_bib36","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1200\/JCO.24.00961","article-title":"Improving access to patient-focused, decentralized clinical trials requires streamlined regulatory requirements: an ASCO research statement","volume":"42","author":"Thota","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105545_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00021","article-title":"Impact of the COVID-19 pandemic mitigation strategies on cancer treatment trials: a meta-analysis of industry and national cancer institute studies","volume":"1","author":"Unger","year":"2025","journal-title":"JCO Oncol. Adv."},{"key":"10.1016\/j.critrevonc.2026.105545_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"Role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105545_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/d41573-020-00093-1","article-title":"Impact of COVID-19 on oncology clinical trials","volume":"19","author":"Upadhaya","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105545_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41746-024-01214-5","article-title":"Lessons learned from an unsuccessful decentralized clinical trial in oncology","volume":"7","author":"Valachis","year":"2024","journal-title":"Npj Digit. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:57:15Z","timestamp":1793087835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"alternative-id":["S1040842826004324"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105545","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From site-centered to patient-centered: Promises and challenges of decentralized clinical trials in oncology","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105545"}}